凯杰

?? 59% of you chose the wrong option! A few days ago, we asked: Which infectious disease is the world’s leading killer? The answer: #TB (#Tuberculosis). ? ?? TB claims over a million lives every year, yet it is preventable and curable. The fight against TB needs innovation, collaboration and action — and you can be part of it. ? ? Learn more about the World TB Day event by QIAGEN on March 24, where we’ll bring together global experts and highlight powerful TB initiatives from around the world. ? Register now ?? https://lnkd.in/eUBATvmM

?? Bacterial infections like Bordetella pertussis often mimic other respiratory illnesses. This makes them easy to miss without syndromic testing. ? In this video, a pediatrician shares a real case where delayed diagnosis of pertussis led to severe consequences – and how syndromic testing can support early and accurate detection. ?? Watch the full story to see why syndromic testing matters. The right time for syndromic testing? Right now. Learn how you can bring this technology to your lab ?? https://lnkd.in/eDPPPGxn

?? Did you know that one infectious disease claims more lives than any other? Cast your vote below and find out the answer here ?? https://lnkd.in/eafRkstm

?? NGS or dPCR? Why not both? Combine NGS’s broad detection with dPCR’s precision to enhance biomarker monitoring. This synergy enables quick validation, empowering longitudinal clinical testing with high accuracy and impact. Dive into the details here ?? https://lnkd.in/eCs38yid ? NGS brings the big picture, scanning the genetic landscape to detect biomarkers with incredible breadth. ? dPCR zooms in to validate biomarkers with accuracy, quantifying them so you can monitor their levels over time with high precision. ?? Together, NGS and dPCR are the perfect pair for: ? Uncovering mutations to validate ? Confirming findings with pinpoint precision ? Speeding up results while saving on costs From discovery to longitudinal testing, NGS and dPCR take the best of both worlds to deliver an impactful biomarker monitoring workflow.?

?? Exciting news from Down Under! We are expanding our bioinformatics footprint with a brand-new data center in Melbourne!?Learn more??? https://lnkd.in/eJN-MnEU ? What this means for our global bioinformatics infrastructure: ? We are strengthening our global bioinformatics leadership position in the Australia/Asia-Pacific region. ? In-country data hosting ensures faster, secure, and compliant omics data analysis and interpretation, compliant with Australian privacy and health regulations. ? We are expanding our global network of seven data centers, ensuring top-tier security and operational excellence worldwide. With 25+ years of experience, 90,000+ users, and 4 million+ profiled patient cases, our bioinformatics business is driving the future of genomics and personalized medicine.

Flu is getting a lot of attention, but our epidemiology data tells a bigger story: ?? 53% of respiratory illnesses so far this year weren’t linked to Flu A/B, RSV or SARS-CoV-2 ?? ~15% were caused by bacteria, including M. pneumoniae and B. pertussis ? Delayed detection = delayed treatment for critical patients That’s where QIAstat-Dx syndromic testing comes in. ?? Detects >20 viruses and bacteria in one fast test ?? Helps clinicians make quicker, more confident treatment decisions The right time for syndromic testing? Right now. Learn more ?? https://lnkd.in/erjuCs2c

Imagine a moment when a patient’s life is in your hands. But you have no fast, reliable way to figure out what’s wrong. Is it a life-threatening infection that needs urgent treatment, or just a natural immune response after surgery? Hours of waiting for test results could mean the difference between life and death. ? This was the challenge that Tim Sweeney, physician and researcher, faced time and time again. He realized that traditional diagnostic methods were slow and often inaccurate—and in some cases, by the time a definitive diagnosis was made, it was already too late. ? But what if we could decode the immune system’s response through gene expression—before any traditional test results came back? ? How did Sweeney crack this puzzle? ?? https://lnkd.in/eY7y-8qB

Let’s talk #HPV beyond cervical cancer, and beyond women. This HPV awareness day, take action by joining experts in a discussion about tackling HPV screening challenges and innovations for both genders. Register now ?? https://lnkd.in/eTRsQdKb ? Let’s gather Mar. 4 to share knowledge about reducing risks for HPV for both men and women. Join our round table discussion with a panel of experts as we explore HPV’s role in various cancers, screening advances and your pressing questions. Why should you attend our Mar. 4 HPV round table discussion? ? Explore challenges in HPV screening and surveillance for both men and women. ? Understand HPV’s impact on multiple cancers. ? Discover early detection breakthroughs from experts. ? Engage in an interactive Q&A session. #cervicalcancer

Exciting news! We delivered solid Q4 2024 growth ahead of our outlook. Learn more ?? https://lnkd.in/eTjffUwg ? Q4 2024: Net sales of $521 million (+2% actual rates, +4% constant exchange rates (CER) core growth); diluted EPS of $0.39 and adjusted diluted EPS of $0.61 ? Net sales of $525 million CER ahead of outlook for at least $520 million CER and adjusted diluted EPS of $0.61 CER ahead of outlook for at least $0.60 CER. ? QIAstat-Dx, QuantiFERON and QIAcuity digital PCR continue double-digit growth pace. ? 30.6% adj. operating income margin up 2.6 percentage points vs. 28.0% in Q4 2023. ? FY 2024: Exceeded outlook for sales and adj. EPS; adj. operating income margin improves 1.8 percentage points to 28.7%. ? Free cash flow rises 63% to $506 million. ? 2025 outlook for about 4% CER sales growth (about +5% CER core sales growth) and adj. diluted EPS of at least $2.28 CER; targeting adj. operating income margin improvement of at least 150 basis points.

Any way you answer, there’s always more to uncover! ? Join our expert-led HPV Awareness Day round table discussion coming up on Mar. 4 to explore: ??HPV’s impact beyond cervical cancer. ??Advances in screening, surveillance and prevention. ??Challenges in gender-inclusive testing. Let’s join together in conversation to raise HPV awareness and improve prevention. Register now ?? https://lnkd.in/eTRsQdKb #HPVAwareness #HPVPrevention?